AMES, Iowa, Nov. 03, 2015 (GLOBE NEWSWIRE) -- NewLink Genetics Corporation (NASDAQ:NLNK), a biopharmaceutical company at the forefront of developing and commercializing novel immuno-oncology product candidates, including both cellular immunotherapy and checkpoint inhibitor platforms, to improve the lives of patients with cancer, today reported consolidated financial results for the third quarter of 2015 and progress in its proprietary and partnered clinical development programs.
“Our dynamic and experienced team has made significant progress in driving our broad clinical development programs,” said Charles Link, M.D., Chairman and Chief Executive Officer. “We look forward to reporting on our strong pipeline of clinical data over the coming year.” - See more at: http://www.globenewswire.com/news-release/2015/11/03/782856/0/en/NewLink-Genetics-Corporation-Provides-Operational-Update-and-Reports-Third-Quarter-2015-Financial-Results.html#sthash.y1aQCW5C.dpuf
Help employers find you! Check out all the jobs and post your resume.
